STERIS plc $STE Stock Position Raised by Locust Wood Capital Advisers LLC

Locust Wood Capital Advisers LLC boosted its holdings in shares of STERIS plc (NYSE:STE) by 5.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 439,731 shares of the medical equipment provider’s stock after buying an additional 23,143 shares during the period. STERIS makes up about 2.7% of Locust Wood Capital Advisers LLC’s holdings, making the stock its 16th biggest position. Locust Wood Capital Advisers LLC owned approximately 0.45% of STERIS worth $108,807,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of STE. Jones Financial Companies Lllp increased its holdings in shares of STERIS by 46.1% during the 1st quarter. Jones Financial Companies Lllp now owns 1,106 shares of the medical equipment provider’s stock valued at $251,000 after acquiring an additional 349 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of STERIS by 32.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 242,732 shares of the medical equipment provider’s stock valued at $55,015,000 after purchasing an additional 59,264 shares in the last quarter. Empowered Funds LLC raised its stake in shares of STERIS by 16.1% in the first quarter. Empowered Funds LLC now owns 2,303 shares of the medical equipment provider’s stock valued at $522,000 after acquiring an additional 319 shares during the last quarter. Woodline Partners LP grew its holdings in shares of STERIS by 40.0% during the first quarter. Woodline Partners LP now owns 8,300 shares of the medical equipment provider’s stock worth $1,881,000 after purchasing an additional 2,372 shares during the last quarter. Finally, Jane Street Group LLC grew its stake in shares of STERIS by 38.9% during the first quarter. Jane Street Group LLC now owns 20,716 shares of the medical equipment provider’s stock valued at $4,695,000 after purchasing an additional 5,803 shares during the last quarter. Hedge funds and other institutional investors own 94.69% of the company’s stock.

Insider Buying and Selling

In other STERIS news, VP Julia Madsen sold 5,008 shares of the stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $262.00, for a total value of $1,312,096.00. Following the transaction, the vice president owned 10,710 shares in the company, valued at approximately $2,806,020. This represents a 31.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Renato Tamaro sold 5,036 shares of the stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $257.55, for a total value of $1,297,021.80. Following the completion of the sale, the vice president directly owned 5,695 shares of the company’s stock, valued at approximately $1,466,747.25. This trade represents a 46.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 25,044 shares of company stock valued at $6,586,218 over the last 90 days. 1.07% of the stock is owned by insiders.

STERIS Stock Up 1.2%

STE stock opened at $261.16 on Thursday. The firm has a market capitalization of $25.63 billion, a PE ratio of 37.52 and a beta of 1.03. The business’s 50 day simple moving average is $258.82 and its 200 day simple moving average is $247.19. STERIS plc has a 1-year low of $204.90 and a 1-year high of $269.44. The company has a current ratio of 2.37, a quick ratio of 1.63 and a debt-to-equity ratio of 0.27.

STERIS (NYSE:STE) last issued its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $2.47 EPS for the quarter, beating analysts’ consensus estimates of $2.38 by $0.09. The firm had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. STERIS had a return on equity of 14.43% and a net margin of 12.07%.During the same period in the prior year, the firm posted $2.14 EPS. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. As a group, research analysts anticipate that STERIS plc will post 9.08 EPS for the current year.

STERIS Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, December 18th. Shareholders of record on Tuesday, November 18th were issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend was Tuesday, November 18th. STERIS’s payout ratio is presently 36.21%.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “buy (b)” rating on shares of STERIS in a research report on Friday, January 9th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $273.50.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.